There is no clinically established „cycle length” for CJC-1295 or ipamorelin, and this article does not give a recommended number of weeks or months by which to use these compounds. This is because no published human studies have tested a long-term standalone administration protocol for either one. What studies do confirm is a general response regarding timing relative to the body's natural hormonal rhythms, which is discussed further on.
How long should CJC-1295 and ipamorelin be used?
The honest answer is that this question cannot be answered with a specific duration. Published human studies for CJC-1295 and Ipamorelin have been short, controlled scientific investigations, not long-term use protocols designed to be taken indefinitely by individuals outside of medical supervision. The primary human study for CJC-1295 was organised as two separate studies lasting 28 and 49 days respectively. Researchers were testing single doses and a small number of weekly or bi-weekly repeated doses to observe the hormone response curve within that time frame. This was a research design aimed at characterising the pharmacology—not demonstrating that longer or repeated use for months is safe or effective [1].
Similarly, the clinical trial of ipamorelin in surgical patients lasted a maximum of seven days or until hospital discharge, reflecting its specific short-term medical purpose (aiding recovery of gastrointestinal function post-surgery), rather than an extended wellness or performance enhancement protocol [2].
Because none of these compounds have been studied for months or years of continuous or cyclical use in humans, there is no scientific basis for stating how long someone „should” or safely „can” use them. Any specific duration suggested elsewhere should be considered as not stemming from peer-reviewed clinical literature.
How long is the CJC-1295 and ipamorelin cycle?
The concept of a „cycle” – a defined period of use followed by a break – is a common framework in bodybuilding and performance enhancement contexts. However, it is not a concept that has been tested or validated in clinical trials for CJC-1295 or ipamorelin. Therefore, no specific cycle length, either within this article or in the broader scientific literature, can be presented as evidence-based. The closest available benchmarks remain the study durations described above: 28–49 days for CJC-1295 under clinical conditions [1], and up to seven days for ipamorelin in a hospital-supervised surgical setting [2]. Neither of these reflects a „cycle” in the bodybuilding sense of repeated on/off periods over a longer duration. No studies have examined what happens with repeated cycling, extended use beyond these timeframes, or a subsequent „off-cycle” period for either of these compounds.
Reviews covering this peptide category have specifically noted that details such as treatment duration remain unknown in the clinical literature. This reinforces the fact that any specific number for cycle length circulating in commercial or informal sources is not something this paper can validate based on actual evidence [3].
When should CJC-1295 be taken?
Although a specific cycle length cannot be provided, there is a scientifically justified, general principle behind the common suggestion to take growth hormone-stimulating peptides in the evening or before sleep. Growth hormone is naturally released by the body in its largest pulses during deep sleep – a well-established feature of normal human physiology. Aligning administration with the body's natural nocturnal hormonal rhythm is therefore a reasonable and widely discussed justification. It is important, however, to maintain precision at this juncture. The primary human studies on CJC-1295 do not specify a particular time of day as part of a validated protocol. The main study focused on measuring the hormonal response curve after administration, rather than establishing an optimal time-of-day recommendation [1].
Similarly, ipamorelin pharmacokinetic studies have measured a rapid peak – around 40 minutes post-administration – and a short half-life of approximately two hours. This describes how quickly the compound acts once administered, but it is not in itself a study comparing morning versus evening dosing outcomes [4].
Although the suggestion of evening timing therefore has a logical basis in general sleep physiology and growth hormone, it should be understood as an extrapolation from this broader physiological principle, rather than a discovery directly confirmed by a dedicated timing study for either of these compounds.
Limitations of current evidence
In all three questions the same gap recurs. Clinical trials for CJC-1295 and ipamorelin were designed to characterise short-term hormonal pharmacology, not to establish safe or effective patterns of long-term use, cycle length or optimal dosing timing.
No published study has tracked outcomes for months of continuous or cyclical use, and no study has directly compared different times of day for dosing either of these compounds. Reviews of this peptide category consistently identify duration and frequency of use as open, unresolved questions in the literature – rather than established details [3].
Disclaimer
This content is for educational purposes only and does not constitute medical advice, a usage protocol, or a therapeutic recommendation. CJC-1295 and ipamorelin are research compounds and are not approved by the FDA or the European Medicines Agency for any medical use, whether used individually or in combination. No published human studies have established safe or effective cycle lengths, duration of use, or timing protocols for either compound outside of short-term, medically supervised research conditions.
References
[1] Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group. (2014). Prospective, randomised, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8
[3] Mayfield, C. K., Bolia, I. K., Feingold, C. L., Lin, E. H., Liu, J. N., Hatch, G. F. R., Gamradt, S. C., & Weber, A. E. (2026). Injectable peptide therapy: A primer for orthopaedic and sports medicine physicians. American Journal of Sports Medicine, 54(1), 223–229. https://doi.org/10.1177/03635465251357593
Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modelling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402